ATRC vs MDT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MDT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ATRC and MDT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ATRC and MDT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AtriCure, based in Mason, Ohio, makes devices that cardiac and thoracic surgeons use in the operating room. Its products fall into four franchises. Appendage management, led by the AtriClip family, closes off the left atrial appendage, the small pouch in the heart where most AF-related clots form, and is now the largest line at ~$64 million a quarter. Open ablation (the Isolator Synergy clamps and EnCompass clamp) lets surgeons create scar lines that block erratic electrical signals during open-heart surgery, and Isolator Synergy was the first FDA-approved device for persistent AF. Pain management, built around the cryoSPHERE probes, freezes intercostal nerves to reduce pain after chest surgery and is the fastest-growing franchise. Minimally invasive ablation, including the Hybrid AF Therapy combining surgical and catheter work, is the one line in decline.

Full ATRC guide

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans three main areas after October 2026: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), and Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform). Its former Diabetes unit (insulin pumps and continuous glucose monitoring) was carved out as MiniMed, which listed on Nasdaq under MMED; on October 15, 2026 Medtronic exchanged its remaining 252.8 million MiniMed shares for Medtronic shares in an exchange offer that was 5.4 times subscribed, so it no longer owns any of MiniMed. The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics, with trailing revenue of about $37.5 billion as of October 2026.

Full MDT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ATRC drivers: AtriClip and the appendage franchise; LeAAPS and BoxX-NoAF: expanding the patient pool.
• MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most visible competitive risk is pulsed field ablation. For MDT, medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ATRC if you believe its drivers more; MDT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ATRC and MDT guides.

ATRC. AtriCure is valued as a growth franchise, not on current earnings. With 2026 adjusted EPS guided to ~$0.24 to $0.32 and GAAP EPS to ~$0.05 to $0.13, a price-earnings ratio is not very informative, so investors tend to look at sales and EBITDA multiples. At ~5x trailing sales and roughly 30x the midpoint of 2026 adjusted EBITDA guidance, the stock trades well above the medical equipment average of under 3x sales. That premium reflects ~77% gross margins, a dominant surgical appendage share and trial optionality. Figures are approximate as of October 2026.

MDT. At about $95 on October 16, 2026, Medtronic trades near 15 times forward earnings, a moderate multiple next to faster-growing medtech peers, while the GAAP trailing P/E of about 23x includes acquisition amortization. The 25 analysts tracked by Yahoo Finance hold a mean target near $104. The next report, expected around November 17, 2026, will be the first read on the company after the MiniMed exit, with consensus at about $1.33 of EPS on $9.5 billion of revenue.

Headline figures (approximate, October 2026): ATRC shows revenue (ttm) ~$570 million (FY2025 ~$534.5M; Q2 2026 ~$153.6M, up 12.8%), 2026 revenue guidance ~$602 million to $610 million (~13% to 14% growth), gross margin ~77.2% in Q2 2026, up ~270 bps YoY, adjusted ebitda ~$27.3M in Q2 2026; 2026 guide ~$85M to $89M; MDT shows revenue (ttm) ~$37.5 billion, up ~14% year over year in the July 2026 quarter, margins ~65% gross, ~19% operating, ~14% net, net income (ttm) ~$5.2 billion, eps ~$4.07 GAAP trailing; ~$6.41 forward estimate.

ATRC and MDT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ATRC and MDT exposure against your real portfolio. It is not an investment adviser.